Cancer medicine had an extraordinary weekend in Madrid. At the European Society for Medical Oncology Congress, Amgen’s Imdelltra, added to AstraZeneca’s Imfinzi as maintenance therapy for extensive-stage small-cell lung cancer, cut the risk of death by 58%. Median survival rose from just under 13 months to a little over 21 months. Then came another landmark […]
Cancer medicine had an extraordinary weekend in Madrid. At the European Society for Medical Oncology Congress, Amgen’s Imdelltra, added to AstraZeneca’s Imfinzi as maintenance therapy for extensive-stage small-cell lung cancer, cut the risk of death by 58%. Median survival rose from just under 13 months to a little over 21 months. Then came another landmark […]
<iframe src="https://statesidedaily.com/embed/cluster/9f1dcf26cf999791a2886ef0e8e2b87afe621191" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="mRNA shouldn’t have a party affiliation"></iframe>
